Literature DB >> 1386845

Severe hypercalcaemia four months after acute oliguric renal failure--successful treatment with intravenous clodronate.

G Crowe1, R Spedding, D R McCance, S J Rankin, A B Atkinson.   

Abstract

A 33 year old man developed acute oliguric failure lasting 66 days, eight days after admission with multiple gun shot wounds. On day 99 after admission, serum calcium was elevated mildly at 2.54 mmol/l (normal range 2.1-2.5 mmol/l). Serum parathormone was undetectable. He was discharged soon afterwards. He presented again on day 164 with nausea, vomiting and blurred vision. Fundoscopy revealed an ischaemic retinopathy and extensive keratopathy. Serum calcium was 3.48 mmol/l and serum creatinine 262 umol/l (normal range 40-110 umol/l). Repeat parathormone was undetectable and there was no evidence of myeloma, sarcoidosis or malignancy. Following treatment with intravenous saline and frusemide, serum calcium fell to a nadir of 3.05 mmol/l. On day 168 an infusion of sodium clodronate 300 mg was given. Twenty-four hours later serum calcium was 2.65 mmol/l and 48 hours later calcium was 2.26 mmol/l. Normocalcaemia was maintained for 17 days and severe hypercalcaemia never recurred. This is the first report in which biphosphonates have been successfully used to treat hypercalcaemia following acute renal failure thus obviating the need for further dialysis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1386845     DOI: 10.1007/bf02996206

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  20 in total

1.  Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate.

Authors:  S J Gallacher; S H Ralston; F J Dryburgh; F C Logue; B F Allam; B F Boyce; I T Boyle
Journal:  Postgrad Med J       Date:  1990-11       Impact factor: 2.401

2.  Hypercalcemia of acute renal failure. Clinical significance and pathogenesis.

Authors:  A de Torrente; T Berl; P D Cohn; E Kawamoto; P Hertz; R W Schrier
Journal:  Am J Med       Date:  1976-07       Impact factor: 4.965

3.  Dichloromethylene diphosphonate action in hematologic and other malignancies.

Authors:  R E Canfield; E S Siris; T P Jacobs
Journal:  Bone       Date:  1987       Impact factor: 4.398

4.  Treatment of skeletal disease in breast cancer: a controlled clodronate trial.

Authors:  I Elomaa; C Blomqvist; L Porkka; C Lamberg-Allardt; G H Borgström
Journal:  Bone       Date:  1987       Impact factor: 4.398

5.  Hypercalcemia during resolution of acute renal failure associated with rhabdomyolysis: evidence for suppression of parathyroid hormone and calcitriol.

Authors:  R L Prince; B G Hutchison; C I Bhagat
Journal:  Aust N Z J Med       Date:  1986-08

6.  Hypocalcemia and hypercalcemia in patients with rhabdomyolysis with and without acute renal failure.

Authors:  M Akmal; J E Bishop; N Telfer; A W Norman; S G Massry
Journal:  J Clin Endocrinol Metab       Date:  1986-07       Impact factor: 5.958

7.  Hypercalcaemia in association with renal failure: the role of immobilisation.

Authors:  R L Prince; J A Eisman; R W Simpson
Journal:  Aust N Z J Med       Date:  1983-02

8.  Delayed hypercalcemia after non-oliguric acute renal failure associated with rhabdomyolysis.

Authors:  J Agnholt; P T Andersen; L K Nielsen
Journal:  Acta Med Scand       Date:  1988

9.  Resolution of muscle calcification in rhabdomyolysis and acute renal failure.

Authors:  M Akmal; D A Goldstein; N Telfer; E Wilkinson; S G Massry
Journal:  Ann Intern Med       Date:  1978-12       Impact factor: 25.391

10.  The pathophysiology of altered calcium metabolism in rhabdomyolysis-induced acute renal failure. Interactions of parathyroid hormone, 25-hydroxycholecalciferol, and 1,25-dihydroxycholecalciferol.

Authors:  F Llach; A J Felsenfeld; M R Haussler
Journal:  N Engl J Med       Date:  1981-07-16       Impact factor: 91.245

View more
  1 in total

Review 1.  Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.